Baillie Gifford & CO Guardant Health, Inc. Transaction History
Baillie Gifford & CO
- $127 Billion
- Q4 2024
A detailed history of Baillie Gifford & CO transactions in Guardant Health, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 5,449,100 shares of GH stock, worth $234 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
5,449,100
Previous 5,872,024
7.2%
Holding current value
$234 Million
Previous $135 Million
23.64%
% of portfolio
0.13%
Previous 0.1%
Shares
5 transactions
Others Institutions Holding GH
# of Institutions
347Shares Held
120MCall Options Held
793KPut Options Held
1.85M-
Vanguard Group Inc Valley Forge, PA12.1MShares$517 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.2MShares$482 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.42MShares$275 Million8.64% of portfolio
-
Cadian Capital Management, LP New York, NY5.22MShares$224 Million9.25% of portfolio
-
Wellington Management Group LLP Boston, MA4.85MShares$208 Million0.03% of portfolio
About Guardant Health, Inc.
- Ticker GH
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 102,220,000
- Market Cap $4.38B
- Description
- Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...